FIELD: medicine; immunology.
SUBSTANCE: group of inventions can be used for induction of immune tolerance. For this purpose, the pharmaceutical composition for inducing immune tolerance contains an effective amount of a population of denucleated erythroid cells, where denucleated erythroid cells contain a fused polypeptide which contains an exogenous antigen, selected from oligodendrocyte myelin glycoprotein and myelin basic protein, or antigenic fragment thereof, and a pharmaceutically acceptable carrier. Group of inventions also relates to a method of producing said composition and use thereof for treating multiple sclerosis in a patient.
EFFECT: use of this group of inventions enables to apply the declared composition for treating multiple sclerosis, providing immune tolerance by stimulating an immunosuppressive phenotype in antigen-presenting cells.
33 cl, 79 ex, 23 tbl, 13 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| FUNCTIONALIZED ERYTHROID CELLS | 2018 |
|
RU2779315C2 |
| ARTIFICIAL ANTIGEN-PRESENTING CELLS AND METHODS FOR THEIR APPLICATION | 2018 |
|
RU2763798C1 |
| NOVEL METHOD FOR PRODUCING DIFFERENTIATED CELLS | 2010 |
|
RU2661107C1 |
| NOVEL METHOD FOR PRODUCING DIFFERENTIATED CELLS | 2010 |
|
RU2603094C2 |
| COMPOSITIONS AND METHODS OF IMMUNOTHERAPY | 2014 |
|
RU2680010C2 |
| LABELED CHIMERIC EFFECTOR MOLECULES AND RECEPTORS THEREOF | 2014 |
|
RU2729463C2 |
| COMPOSITIONS AND METHODS FOR BOOSTING THE EFFECTIVENESS OF ADOPTIVE CELL IMMUNOTHERAPY | 2015 |
|
RU2716716C2 |
| INTRACELLULAR DELIVERY OF BIOLOGICAL MOLECULES FOR TOLERANCE INDUCING | 2017 |
|
RU2770492C2 |
| PHARMACEUTICAL COMPOSITION POSSESSING ANTITUMOUR EFFECT, AND METHOD FOR REDUCING PD-L1 INHIBITING EFFECT ON HUMAN T-CELLS | 2016 |
|
RU2688692C2 |
| METHOD FOR OBTAINING T-CELL RECEPTOR EXPRESSING CELLS | 2013 |
|
RU2665548C2 |
